← Leaderboards
Chang Han
University Of Pittsburgh At Pittsburgh
$150,298
Attributed
$150,298
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $75.8K · FY2009–10$100K$75K$50K$25K$0
'09
'10
Funding mix
By agency
NIH$150,298 · 1
By mechanism
R03$150,298 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Kari N Nejak-Bowen$7,645,432
- Sungjin Ko$2,106,701
- Xiao-Ming Yin$8,248,383
- M. Ilyas Kamboh$33,365,358
- Henri R Ford$5,201,366
Others in their field
Top investigators on “Bay 54-9085”
- Ross Leigh Cagan · Washington University$8,688,632
- Amaia Lujambio · Icahn School Of Medicine At Mount Sinai$5,283,950
- Mark J Ratain · University Of Chicago$4,695,781
- Ahmed Kaseb · University Of Tx Md Anderson Can Ctr$3,333,430
- Thomas E. Witzig · Mayo Clinic Coll Of Medicine, Rochester$3,169,864
- Aimee Marie Crago · Sloan-Kettering Inst Can Research$2,751,471
Research focus
Bay 54-9085Malignant Neoplasm Of LiverCancer ChemopreventionAdverse EffectsBiliaryCancer Cell GrowthCarcinogenesis InhibitionCarcinogenesisCyclooxygenase 2CarcinogensCarcinomaCardiovascular SystemChemopreventionCholangiocarcinomaChronicBaseChronic Hepatitis CCoxibsAnimal ModelDiethylnitrosamineDinoprostoneDoseDysplasiaEpithelial
Grant awards (3)
Inhibition of EP1 in conjunction with Sorafenib for liver cancer chemoprevention$74,548
R03 · FY2010 · CA · contact PI
Inhibition of EP1 in conjunction with Sorafenib for liver cancer chemoprevention$60,021
R03 · FY2009 · CA · contact PI
Inhibition of EP1 in conjunction with Sorafenib for liver cancer chemoprevention$15,729
R03 · FY2009 · CA · contact PI